A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288

Trial Profile

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs CV 301 (Primary) ; Nivolumab (Primary) ; Fluorouracil; Folic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 New trial record
    • 08 Mar 2018 According to a Bavarian Nordic media release, enrolment is anticipated to initiate before mid-year 2018. This trail will be led by Darren R. Carpizo at Rutgers Cancer Institute in New Jersey.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top